AVEO PHARMACEUTICALS INC (AVEO) Stock Price, Quote, News and Overview
NASDAQ:AVEO - Nasdaq - US0535883070 - Common Stock - Currency: USD
AVEO Quote, Performance and Key Statistics
15
0 (0%)
The current stock price of AVEO is 15 USD. In the past month the price increased by 0.6%. In the past year, price increased by 338.6%.
AVEO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AVEO
Company Profile
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2010-03-12. The firm is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The firm markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The company also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).
Company Info
AVEO PHARMACEUTICALS INC
30 Winter Street
Boston MASSACHUSETTS 02108 US
CEO: Michael Bailey
Employees: 114
Company Website: http://www.aveooncology.com/
Phone: 18574000101.0
AVEO PHARMACEUTICALS INC / AVEO FAQ
What is the stock price of AVEO PHARMACEUTICALS INC today?
The current stock price of AVEO is 15 USD.
What is the ticker symbol for AVEO PHARMACEUTICALS INC stock?
The exchange symbol of AVEO PHARMACEUTICALS INC is AVEO and it is listed on the Nasdaq exchange.
On which exchange is AVEO stock listed?
AVEO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AVEO PHARMACEUTICALS INC stock?
10 analysts have analysed AVEO and the average price target is 15.3 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 15. Check the AVEO PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AVEO PHARMACEUTICALS INC worth?
AVEO PHARMACEUTICALS INC (AVEO) has a market capitalization of 521.45M USD. This makes AVEO a Small Cap stock.
How many employees does AVEO PHARMACEUTICALS INC have?
AVEO PHARMACEUTICALS INC (AVEO) currently has 114 employees.
What are the support and resistance levels for AVEO PHARMACEUTICALS INC (AVEO) stock?
AVEO PHARMACEUTICALS INC (AVEO) has a support level at 14.96 and a resistance level at 15.01. Check the full technical report for a detailed analysis of AVEO support and resistance levels.
Is AVEO PHARMACEUTICALS INC (AVEO) expected to grow?
The Revenue of AVEO PHARMACEUTICALS INC (AVEO) is expected to grow by 163.12% in the next year. Check the estimates tab for more information on the AVEO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AVEO PHARMACEUTICALS INC (AVEO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AVEO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AVEO, evaluating the profitability, health, valuation and growth aspects
- AVEO PHARMACEUTICALS INC (AVEO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AVEO PHARMACEUTICALS INC (AVEO) Sales and EPS estimates to see what analysts future expectations are.
- AVEO PHARMACEUTICALS INC (AVEO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AVEO PHARMACEUTICALS INC (AVEO) Insider and Institutional Ownership to learn about the owners and their transactions.
- AVEO PHARMACEUTICALS INC (AVEO) Stock Chart to make your own analysis
- AVEO PHARMACEUTICALS INC (AVEO) Latest news and press-releases to stay up to date.
Does AVEO PHARMACEUTICALS INC (AVEO) stock pay dividends?
AVEO does not pay a dividend.
When does AVEO PHARMACEUTICALS INC (AVEO) report earnings?
AVEO PHARMACEUTICALS INC (AVEO) will report earnings on 2023-03-13.
What is the Price/Earnings (PE) ratio of AVEO PHARMACEUTICALS INC (AVEO)?
AVEO PHARMACEUTICALS INC (AVEO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).
AVEO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to AVEO. When comparing the yearly performance of all stocks, AVEO is one of the better performing stocks in the market, outperforming 99.55% of all stocks.
AVEO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVEO. AVEO has a bad profitability rating. Also its financial health evaluation is rather negative.
AVEO Financial Highlights
Over the last trailing twelve months AVEO reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 56.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.94 |
AVEO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 50% to AVEO. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 59.87% and a revenue growth 163.12% for AVEO